Bio/Pharma News

Dec 28, 2017
By Pharmaceutical Technology Editors
Mallinckrodt has agreed to acquire biopharmaceutical company Sucampo Pharmaceuticals for $18 per share, or a transaction value of approximately $1.2 billion.
Dec 20, 2017
By Pharmaceutical Technology Editors
FDA has approved a new gene therapy for treating patients born with a rare, inherited vision loss.
Dec 19, 2017
By Pharmaceutical Technology Editors
The European Commission has closed its infringement procedure against Roche after the company completed remedial actions.
Dec 19, 2017
By Pharmaceutical Technology Editors
The company has completed development of a first-generation production process for its chimeric antigen receptor regulatory T cell product portfolio and is selecting a CMO for clinical supply.
Dec 19, 2017
By Pharmaceutical Technology Editors
Sanofi Genzyme and its partner, Alnylam Pharmaceuticals, have filed a marketing authorization application with EMA for an investigational RNAi therapeutic for treating a genetic-based disease.
Dec 18, 2017
By Pharmaceutical Technology Editors
Cycle and Aprecia will use Aprecia's 3DP Technology to improve rare disease drug formulations.
Dec 18, 2017
By Pharmaceutical Technology Editors
The US Court of Appeals for the Federal Circuit has decided in favor of Novartis’ Sandoz in rendering the opinion that Amgen cannot use state laws to prohibit or delay the marketing of biosimilars.
Dec 14, 2017
By Pharmaceutical Technology Editors
The company is seeking approval from FDA for use of the drug, migalastat, to treat Fabry disease in patients who have amenable mutations.
Dec 13, 2017
By Pharmaceutical Technology Editors
The companies will co-develop and co-commercialize the lead candidate generated from their earlier collaboration to treat genetic blood disorders.
Dec 13, 2017
By Pharmaceutical Technology Editors
In partnership with Indian pharmaceutical firm, Torrent Pharmaceuticals, Novo Nordisk has expanded an insulin manufacturing facility at Torrent’s Indrad, Gujarat, India site.
native1_300x100
lorem ipsum